Posted by Michael Wonder on 09 Sep 2020
Alimera Sciences obtains reimbursement approval for Iluvien use in non-infectious posterior uveitis in Scotland
8 September 2020 - Alimera Sciences announces that the Scottish Medicines Consortium, after completing its assessment and review, has accepted (per label) Iluvien for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
The decision came following a review of a cost-utility analysis for the prevention of relapse in recurrent non-infectious uveitis based on results from the PSV-FAI-001 clinical study.
The analysis compared outcomes following insertion of a fluocinolone acetonide implant at baseline with standard treatment, including systemic corticosteroids or immunosuppressants, topical steroids, intra-ocular pressure reduction therapy, cataract removal and other elective ocular surgical procedures.
